Clinical trial · Observational
Prognosis of METTL-14 in Endometrial Carcinoma
Prognostic Impact of Immunohistochemical Expression of METTL-14 in Endometrial Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. To evaluate immunohistochemical expression of METTL14 in type1 endometrial carcinoma. 2. To evaluate the correlation between METTL14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. To assess correlation of METTL-14 expression with disease free survival and overall survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Adenocarcinoma | Endometrial Adenocarcinoma | CURATED_BROADER | 0.80 |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IHC | Behavioral | — | UNRESOLVED |
| Observation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- endometrial carcinoma
- interventionNames
- Other: Observation
- Behavioral: IHC
Primary outcomes (1)
- measure
- Evaluation of immunohistochemical Expression of METTL14 in Type 1 Endometrial Carcinoma
- timeFrame
- baseline
- description
- Measurement: Percentage of positive METTL14-stained tumor cells using immunohistochemistry (IHC). Unit: Percentage (%). Time Frame: Baseline.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Cases of type1endometrial carcinoma with: 1. Hystrectomy operation 2. Available full clinical data about patient (age, complaint, findings in clinical examination). 3. Full data about previous biopsy and radiology. 4. Full data about patient survival, disease progression and history of chemotherapy for three years. Exclusion Criteria: * 1\. Any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data. 2\. Cases with no available H\&E stained slides or formalin fixed paraffin embedded block. 3.D\&C.
References
Publications (0)
Data not yet available